Victoza(R) (liraglutide) Provides Greater Glycaemic Ccontrol than SGLT-2 Inhibitors

PR62692

VANCOUVER, Canada, Dec. 2/PRNewswire=KYODO JBN/ --

    This material is intended for global medical media only.  

    This material is not approved for Canadian journalists or Canadian

audiences.  

    For journalistic assessment and preparation before publication.  

    New findings from a network meta-analysis show that treatment with

Victoza(R) (liraglutide) provides a greater HbA1c reduction and an improved

likelihood of reaching glycaemic goals compared to sodium-glucose

co-transporter 2 (SGLT-2) inhibitors in people with type 2 diabetes who are

inadequately controlled with metformin alone or in combination with

sulfonylurea, dipeptidyl peptidase-4 (DPP-4) inhibitors or

thiazolidinedione.[1] Findings were presented today at the World Diabetes

Congress of the International Diabetes Federation (IDF) in Vancouver, Canada.

    The meta-analysis evaluated the relative efficacy of Victoza(R) to SGLT-2

inhibitors, including canagliflozin, empagliflozin and dapagliflozin.[1] In an

analysis of 17 randomised controlled trials (RCTs), Victoza(R) demonstrated

greater reductions in mean HbA1c compared to all SGLT-2 inhibitors

(placebo-adjusted mean change -1.01%/-1.18% for Victoza(R) 1.2 mg/1.8 mg;

-0.64%/-0.79% for canagliflozin 100 mg/300 mg; -0.32%/-0.38% for dapagliflozin

5 mg/10 mg; -0.59%/-0.62% for empagliflozin 10 mg/25 mg).[1]

    "In the absence of head-to-head trials, this analysis provides valuable

insight into the comparative outcomes with liraglutide versus SGLT-2 inhibitors

in people with type 2 diabetes uncontrolled on oral antidiabetic treatments,"

said Maria Lorenzi, MSc, lead author and research manager, Redwood Outcomes,

CA, US.

    The networks of evidence analysed to evaluate the relative efficacy of

Victoza(R) compared with approved SGLT-2 inhibitors were based on available

data from RCTs that were published when the meta-analysis was initiated.

    About network meta-analyses   

    In network meta-analyses (NMA), multiple treatments are included, using

data from trials that compare at least two of these treatments. A NMA offers

the advantage of being able to compare any treatments included in the network,

including those that have not been compared directly, and, in the right

circumstances, allows the full set of treatments to be ranked.[2] As with any

NMA, some of the indirect comparisons in the Victoza(R) compared to SGLT-2

inhibitors NMA may be biased due to differences in patient characteristics

between trials, most notably duration of diabetes, and the number of

concomitant oral antidiabetic drugs.

    About Victoza(R)

    Victoza(R) (liraglutide) is a human glucagon-like peptide-1 (GLP-1)

analogue with an amino acid sequence 97% similar to endogenous human GLP-1.

Like natural GLP-1, Victoza(R) works by stimulating the beta-cells to release

insulin and suppressing glucagon secretion from the alpha cells only when blood

sugar levels are high. Due to this glucose-dependent mechanism of action,

Victoza(R) is associated with a low rate of hypoglycaemia.*[3] In addition,

Victoza(R) reduces body weight and body fat mass through mechanisms involving

reduced appetite and lowered energy intake.[3]

    Victoza(R) was launched in the EU in 2009 and is commercially available in

more than 80 countries with more than three million patient years of use in

people with type 2 diabetes globally.[3],[4] In Europe, Victoza(R) is indicated

for treatment of adults with type 2 diabetes to achieve glycaemic control in

combination with oral glucose-lowering medicinal products and/or basal insulin

when these, together with diet and exercise, do not provide adequate glycaemic

control.[3]

    *Hypoglycaemia has primarily been observed when Victoza(R) is combined with

a sulfonylurea or basal insulin.

    About Novo Nordisk    

    Novo Nordisk is a global healthcare company with more than 90 years of

innovation and leadership in diabetes care. This heritage has given us

experience and capabilities that also enable us to help people defeat other

serious chronic conditions: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in

75 countries and markets its products in more than 180 countries. For more

information, visit: novonordisk.com [http://www.novonordisk.com ], Facebook

[http://www.facebook.com/novonordisk ], Twitter

[http://www.twitter.com/novonordisk ], LinkedIn

[http://www.linkedin.com/company/novo-nordisk ], YouTube.

[http://www.youtube.com/novonordisk ]

    Further information

    Media:

    Katrine Sperling             

    +45-4442-6718    

    krsp@novonordisk.com;

    Asa Josefsson                

    +45-3079-7708    

    aajf@novonordisk.com

    Investors:

    Peter Hugreffe Ankersen

    +45-3075-9085    

    phak@novonordisk.com;

    Melanie Raouzeos

    +45-3075-3479  

    mrz@novonordisk.com;

    Daniel Bohsen                

    +45-3079-6376    

    dabo@novonordisk.com;

    Kasper Veje                  

    +45-3079-8519    

    kpvj@novonordisk.com;

    Frank Daniel Mersebach (US)  

    +1-609-235-8567  

    fdni@novonordisk.com

    SOURCE: Novo Nordisk

    References   

    1) Lorenzi M, Ploug U, Langer J, et al. Liraglutide vs SGLT-2 inhibitors in

people with type 2 diabetes: a network meta-analysis. Presented at 23rd World

Diabetes Congress, Vancouver, BC, Canada; 30 November - 4 December 2015.

Abstract number 0226-P.

    2) Jackson D, Barrett J, Rice S, et al. A design-by-treatment interaction

model for network meta-analysis with random inconsistency effects. Stat Med.

2014; 33:3639-3654.

    3) EMA. Victoza(R) EU Summary of Product Characteristics. Available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf

       Last accessed October 2015.

    4) Internal Calculations based on IMS Midas Quantum data. September 2015.